Tejara Capital Ltd Purchases 124,524 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Tejara Capital Ltd increased its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 11.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,225,650 shares of the biotechnology company’s stock after buying an additional 124,524 shares during the period. OPKO Health accounts for 1.2% of Tejara Capital Ltd’s holdings, making the stock its 24th biggest holding. Tejara Capital Ltd owned about 0.18% of OPKO Health worth $1,802,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of OPK. FMR LLC increased its stake in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC bought a new stake in OPKO Health in the third quarter valued at $45,000. Cibc World Markets Corp bought a new stake in OPKO Health in the fourth quarter valued at $45,000. Ieq Capital LLC bought a new stake in OPKO Health in the fourth quarter valued at $52,000. Finally, World Investment Advisors LLC bought a new stake in OPKO Health in the third quarter valued at $61,000. Institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have bought 964,971 shares of company stock worth $1,493,692. 47.26% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on OPK shares. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Stock Up 4.0 %

Shares of NASDAQ OPK opened at $1.81 on Tuesday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -9.53 and a beta of 1.70. The company has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.57. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. On average, equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.